Latest News
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company's chief technical officer, Dr. Marnix Bosch, pr...
Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment
9 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced on Wednesday that the first patient has been successfully dosed in the Phase II clinical trial eval...
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a new partnership.HanchorBio's subsidiary, FBD B...
Keenova reports positive Phase 3 results for XIAFLEX in plantar fibromatosis
8 July 2026 - US-based therapeutics company Keenova Therapeutics plc on Wednesday reported positive Phase 3 results for XIAFLEX, its collagenase treatment for plantar fibromatosis, a chronic condition characterised by collagen-based nodules in the fo...
GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study
8 July 2026 - Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collab...